Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Shares of Biomea Fusion are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.
Stocks · News reference
Biomea Fusion Announces First Participant Dosed In 64-Patient OPAL Study Arm Of Icovamenib Plus Low-Dose Semaglutide vs. Semaglutide Alone In Overweight, Obese Adults
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biomea Fusion shares are trading higher after the company announced the completion of enrollment in COVALENT-211 Phase II clinical trial evaluating icovamenib in insulin-deficient Type 2 diabetes.
Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 76.47 percent increase over losses of $(0.51) per share from